Precision Medicine: Identifying Targeted Cancer Treatments with Genomic Testing

Precision Medicine: Identifying Targeted Cancer Treatments with Genomic Testing

Precision, or personalized, medicine has made a sea-change in cancer treatment. A pipe dream for most patients 10 years ago, it is a reality today. Precision Medicine's keystone is the ability to identify personal gene characteristics and match them to specific treatment options. This discussion will consider many questions surrounding precision medicine and targeted treatment, helping to answer:

  • Genetic (germline) versus genomic (somatic) testing
  • Who should get tested and for what?
  • Getting tested and educating your doctor
  • The pros and cons of testing
  • Is gene testing affordable?
  • What is an actionable mutation?
  • How do actionable mutations impact treatment?
  • Immunotherapy and personalized medicine

We have a knowledgeable panel of physicians, patients and patient advocates to help patients, caregivers and advocates understand precision medicine and targeted treatment, including David Marshak, Manager Patient Advocacy at Foundation Medicine, based in Cambridge, Massachusetts. Foundation Medicine performs comprehensive genomic sequencing to identify the molecular alterations in each patient's unique cancer and match them with relevant targeted therapies, immunotherapies, and clinical trials.

Rick Davis will be moderating the panel. Rick is a nationally recognized patient advocate and Founder of Answer Cancer Foundation. Diagnosed with locally advanced prostate cancer in 2007 and treated with radiation and hormone therapy, Rick moderates AnCan's High Risk/Recurrent/Advanced Prostate Cancer virtual support group, a weekly online & telephone group.    

Panelists

Talk Recorded on May 10, 2017, 6 p.m.   EST 667 10

Hear Talk Audio




  • Anonymous User May 10, 2017, 6:23 p.m.  US/Eastern

    Precision medicine looks at mutations of the human genome. What is the treatment approach for mutations such as cancer that develop during a person’s lifetime?

  • Anonymous User May 10, 2017, 4:54 p.m.  US/Eastern

    I suspect one of the benefits of genomic testing for prostate cancer patients is better identification of treatment protocols. For those of us already treated for prostate cancer, is genomic testing something to be completed now or later in the event of recurrence?

  • Anonymous User May 10, 2017, 3:01 a.m.  US/Eastern

    Will genomic sequencing show if I have a hereditary risk for cancer?

  • Anonymous User May 10, 2017, 3 a.m.  US/Eastern

    What is the cost of genomic sequencing?

  • Anonymous User May 10, 2017, 2:59 a.m.  US/Eastern

    What cancers can be treated with precision medicine?

  • Anonymous User May 10, 2017, 2:27 a.m.  US/Eastern

    What are some of the challenges facing precision medicine ?

  • Anonymous User May 10, 2017, 2:26 a.m.  US/Eastern

    What is the difference between precision medicine and personalized medicine?

  • Anonymous User May 10, 2017, 2:25 a.m.  US/Eastern

    Regarding precision medicine, do you feel that cancer treatment is where it will make the biggest impact, or do you think that other diseases and conditions are as likely to benefit; and do you feel that researchers should concentrate on one disease first?

  • Anonymous User May 10, 2017, 2:24 a.m.  US/Eastern

    How strong do you think the preventive and predictive components of precision medicine are?

  • Kidney Transplant Donor April 29, 2017, 1:12 a.m.  US/Eastern

    Incalculable who are as of now sitting tight for a kidney transplant or taking a gander at the choice to be a living supplier are doing fighting with the way that kidney transplant hold up times are broadening. Essentially imparted, more kidney contributors are required. This device compartment joins essential data to help you better comprehend living kidney favoring. Here we empower the <a href="https://getakidney.org/">Kidney Donors Online</a> organization for the capability of people.